BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 30890141)

  • 1. Genetic variation in the ATP binding cassette transporter ABCC10 is associated with neutropenia for docetaxel in Japanese lung cancer patients cohort.
    Sone K; Oguri T; Uemura T; Takeuchi A; Fukuda S; Takakuwa O; Maeno K; Fukumitsu K; Kanemitsu Y; Ohkubo H; Takemura M; Ito Y; Niimi A
    BMC Cancer; 2019 Mar; 19(1):246. PubMed ID: 30890141
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Genetic variations in the ATP-binding cassette transporter ABCC10 are associated with neutropenia in Japanese patients with lung cancer treated with nanoparticle albumin-bound paclitaxel.
    Horiuchi M; Uemura T; Oguri T; Toda S; Yamamoto S; Suzuki Y; Kagawa Y; Sone K; Fukuda S; Mori Y; Fukumitsu K; Kanemitsu Y; Tajiri T; Ohkubo H; Takemura M; Ito Y; Maeno K; Niimi A
    Invest New Drugs; 2022 Oct; 40(5):934-943. PubMed ID: 35759133
    [TBL] [Abstract][Full Text] [Related]  

  • 3. ABCC10/MRP7 is associated with vinorelbine resistance in non-small cell lung cancer.
    Bessho Y; Oguri T; Ozasa H; Uemura T; Sakamoto H; Miyazaki M; Maeno K; Sato S; Ueda R
    Oncol Rep; 2009 Jan; 21(1):263-8. PubMed ID: 19082471
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Associations of ABCB1, ABCC2, and ABCG2 polymorphisms with irinotecan-pharmacokinetics and clinical outcome in patients with advanced non-small cell lung cancer.
    Han JY; Lim HS; Yoo YK; Shin ES; Park YH; Lee SY; Lee JE; Lee DH; Kim HT; Lee JS
    Cancer; 2007 Jul; 110(1):138-47. PubMed ID: 17534875
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Polymorphisms of Genes Encoding Multidrug Resistance Proteins as a Predictive Factor for Second-Line Docetaxel Therapy in Advanced Non-small Cell Lung Cancer.
    Szczyrek M; Mlak R; Krawczyk P; Wojas-Krawczyk K; Powrózek T; Szudy-Szczyrek A; Zwolak A; Daniluk J; Milanowski J
    Pathol Oncol Res; 2017 Jul; 23(3):607-614. PubMed ID: 27988838
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association of genetic polymorphisms in SLCO1B3 and ABCC2 with docetaxel-induced leukopenia.
    Kiyotani K; Mushiroda T; Kubo M; Zembutsu H; Sugiyama Y; Nakamura Y
    Cancer Sci; 2008 May; 99(5):967-72. PubMed ID: 18294295
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MRP7/ABCC10 expression is a predictive biomarker for the resistance to paclitaxel in non-small cell lung cancer.
    Oguri T; Ozasa H; Uemura T; Bessho Y; Miyazaki M; Maeno K; Maeda H; Sato S; Ueda R
    Mol Cancer Ther; 2008 May; 7(5):1150-5. PubMed ID: 18445659
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The relationship of polymorphisms in ABCC2 and SLCO1B3 with docetaxel pharmacokinetics and neutropenia: CALGB 60805 (Alliance).
    Lewis LD; Miller AA; Owzar K; Bies RR; Markova S; Jiang C; Kroetz DL; Egorin MJ; McLeod HL; Ratain MJ;
    Pharmacogenet Genomics; 2013 Jan; 23(1):29-33. PubMed ID: 23188068
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Abcc10 status affects mammary tumour growth, metastasis, and docetaxel treatment response.
    Domanitskaya N; Wangari-Talbot J; Jacobs J; Peiffer E; Mahdaviyeh Y; Paulose C; Malofeeva E; Foster K; Cai KQ; Zhou Y; Egleston B; Hopper-Borge E
    Br J Cancer; 2014 Aug; 111(4):696-707. PubMed ID: 24937672
    [TBL] [Abstract][Full Text] [Related]  

  • 10. ABCB1 and ABCC2 genetic polymorphism as risk factors for neutropenia in esophageal cancer patients treated with docetaxel, cisplatin, and 5-fluorouracil chemotherapy.
    Nomura H; Tsuji D; Demachi K; Mochizuki N; Matsuzawa H; Yano T; Daiko H; Fujii S; Kojima T; Itoh K; Kawasaki T
    Cancer Chemother Pharmacol; 2020 Aug; 86(2):315-324. PubMed ID: 32748110
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The role of ABCC10/MRP7 in anti-cancer drug resistance and beyond.
    Chen DQ; Xie Y; Cao LQ; Fleishman JS; Chen Y; Wu T; Yang DH
    Drug Resist Updat; 2024 Mar; 73():101062. PubMed ID: 38330827
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Contribution of Abcc10 (Mrp7) to in vivo paclitaxel resistance as assessed in Abcc10(-/-) mice.
    Hopper-Borge EA; Churchill T; Paulose C; Nicolas E; Jacobs JD; Ngo O; Kuang Y; Grinberg A; Westphal H; Chen ZS; Klein-Szanto AJ; Belinsky MG; Kruh GD
    Cancer Res; 2011 May; 71(10):3649-57. PubMed ID: 21576088
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Genetic Variations of Drug Transporters Can Influence on Drug Response in Patients Treated with Docetaxel Chemotherapy.
    Choi JR; Kim JO; Kang DR; Shin JY; Zhang XH; Oh JE; Park JY; Kim KA; Kang JH
    Cancer Res Treat; 2015 Jul; 47(3):509-17. PubMed ID: 25648089
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Japanese subgroup analysis of a phase III study of S-1 versus docetaxel in non-small cell lung cancer patients after platinum-based treatment: EAST-LC.
    Sugawara S; Nakagawa K; Yamamoto N; Nokihara H; Ohe Y; Nishio M; Takahashi T; Goto K; Maemondo M; Ichinose Y; Seto T; Sakai H; Gemma A; Imamura F; Shingyoji M; Saka H; Inoue A; Takeda K; Okamoto I; Kiura K; Morita S; Tamura T
    Int J Clin Oncol; 2019 May; 24(5):485-493. PubMed ID: 30830659
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association of Allelic Interaction of Single Nucleotide Polymorphisms of Influx and Efflux Transporters Genes With Nonhematologic Adverse Events of Docetaxel in Breast Cancer Patients.
    Jabir RS; Ho GF; Annuar MABA; Stanslas J
    Clin Breast Cancer; 2018 Oct; 18(5):e1173-e1179. PubMed ID: 29885788
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Feasibility study of docetaxel plus bevacizumab as first line therapy for elderly patients with advanced non-small-cell lung cancer: Thoracic Oncology Research Group (TORG) 1014.
    Takagi Y; Hosomi Y; Oshita F; Okamoto H; Seki N; Minato K; Aono H; Yamada K; Okuma Y; Hida N; Sakamoto T; Miura Y; Yomota M; Satoh A; Kunitoh H; Sakamaki K; Shibuya M; Watanabe K
    BMC Cancer; 2015 Oct; 15():740. PubMed ID: 26481215
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association of ABCC10 polymorphisms with nevirapine plasma concentrations in the German Competence Network for HIV/AIDS.
    Liptrott NJ; Pushpakom S; Wyen C; Fätkenheuer G; Hoffmann C; Mauss S; Knechten H; Brockmeyer NH; Hopper-Borge E; Siccardi M; Back DJ; Khoo SH; Pirmohamed M; Owen A;
    Pharmacogenet Genomics; 2012 Jan; 22(1):10-9. PubMed ID: 22082652
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A comprehensive study of polymorphisms in ABCB1, ABCC2 and ABCG2 and lung cancer chemotherapy response and prognosis.
    Campa D; Müller P; Edler L; Knoefel L; Barale R; Heussel CP; Thomas M; Canzian F; Risch A
    Int J Cancer; 2012 Dec; 131(12):2920-8. PubMed ID: 22473764
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chemotherapy-induced neutropenia does not correlate with DNA repair gene polymorphisms and treatment efficacy in advanced non-small-cell lung cancer patients.
    Iranzo V; Sirera R; Bremnes RM; Blasco A; Jantus-Lewintre E; Tarón M; Berrocal A; Blasco S; Caballero C; Del Pozo N; Rosell R; Camps C
    Clin Lung Cancer; 2011 Jul; 12(4):224-30. PubMed ID: 21726821
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Influence of ABCB1 C3435T and C1236T gene polymorphisms on tumour response to docetaxel-based neo-adjuvant chemotherapy in locally advanced breast cancer patients of South India.
    Priyadarshini R; Raj GM; Kayal S; Ramesh A; Shewade DG
    J Clin Pharm Ther; 2019 Apr; 44(2):188-196. PubMed ID: 30637776
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.